tiprankstipranks
Advertisement
Advertisement
Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
PremiumThe FlyAurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
29d ago
Aurinia backs FY26 revenue view $315M-$325M, consensus $326.22M
Premium
The Fly
Aurinia backs FY26 revenue view $315M-$325M, consensus $326.22M
29d ago
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline
Premium
Company Announcements
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline
2M ago
Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
PremiumThe FlyAurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
2M ago
Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay
Premium
Company Announcements
Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay
2M ago
MKT Capital ‘applauds’ Aurinia’s management transition
Premium
The Fly
MKT Capital ‘applauds’ Aurinia’s management transition
2M ago
Aurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook
PremiumCompany AnnouncementsAurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook
3M ago
Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c
Premium
The Fly
Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c
3M ago
Aurinia Pharmaceuticals sees 2026 revenue $315M-$-325M, consensus $326.8M
Premium
The Fly
Aurinia Pharmaceuticals sees 2026 revenue $315M-$-325M, consensus $326.8M
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100